In perfused human placentas, pramlintide had an equilibrium fetal-to-maternal concentration ratio of <=0.006.
In plain wordsIn lab tests with human placentas, pramlintide concentrations on the fetal side were very low relative to the maternal side.
- Peptide
- Pramlintide (Symlin)
- Outcome
- Not applicableFetal-to-maternal concentration ratio
- Study
humann: not reported in source
Perfused human placental cotyledons- Outcome group
- Pharmacokinetics · Pharmacology
- Studied dose
- Near the therapeutic plasma concentration and approximately 10-50 times that concentration · Maternal-side cotyledon perfusateAs given in this study (human).
Measurements
- Fetal-to-maternal concentration ratio
- ≤ 0.006 ratio
- Pramlintide during equilibrium perfusion
Source sentences
The ratio of fetal-to-maternal peptide concentrations during equilibrium perfusion were extremely low (pramlintide < or = 0.006, exenatide < or = 0.017).
3 context sentences(design, population, supporting numbers)
This was examined using ex vivo perfusions of human placentas.
Either pramlintide or exenatide was then added to each acceptable cotyledon perfusate on the maternal side.
Each peptide was evaluated at an initial concentration near the therapeutic plasma concentration and at approximately 10-50 times that concentration in each of the three cotyledons.